West Virginia legislation · 2026 Regular Session
West Virginia HB4626: Relating to the establishment of a grant program to fund the United States Food and Drug Administration’s drug development trials with ibogaine
Status: Vetoed, April 1, 2026
What the bill says
An act to amend the Code of West Virginia, 1931, as amended, by adding a new article, designated §16-67-1, §16-67-2, §16-67-3, §16-67-4, §16-67-5, §16-67-6, and §16-67-7, relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine; the preparation and notice of funding opportunity; application requirements; the creation of a selection committee; the submission of an investigational new drug application with the United States Food and Drug Administration; requesting a breakthrough therapy designation for ibogain.
From the enrolled text, March 12, 2026:
AN ACT to amend the Code of West Virginia, 1931, as amended, by adding a new article, designated §16-67-1, §16-67-2, §16-67-3, §16-67-4, §16-67-5, §16-67-6, and §16-67-7, relating to the establishment of a grant program to fund the United States Food and Drug Administration's drug development trials with ibogaine; the preparation and notice of funding opportunity; application requirements; the creation of a selection committee; the submission of an investigational new drug application with the United States Food and Drug Administration; requesting a breakthrough therapy designation for ibogaine from the United States Food and Drug Administration; the establishment of drug development trial sites; conducting drug development trials; the selection of an institutional review board; and funding. Article 67. Grant Program for Drug Development of Ibogaine Treatment. §16-67-1. Establishment of Grant Program. The Secretary of Health shall establish and administer a grant program to fund a public-private partnership program that will pay for the costs of the United States Food and Drug Administration's drug development trials with ibogaine to secure the administration's approval as a medication for treatment of opioid use disorder, co-occurring substance use disorder, and any other neurological or mental health conditions for which ibogaine demonstrates efficacy. §16-67-2. Application. (a) The secretary shall prepare and issue a notice of funding opportunity to solicit applications for the grant program established under this …